期刊文献+

杜氏利什曼原虫无鞭毛体蛋白基因重组质粒的免疫原性研究 被引量:3

Immunogenicity of the Recombinant Plasmid of Leishmania donovani Amastin Gene
下载PDF
导出
摘要 目的研究杜氏利什曼原虫无鞭毛体蛋白基因重组质粒pcDNA3.1-amastin的免疫原性。方法将18只雌性BALB/c小鼠随机分为实验组和对照组,每组9只。两组分别肌肉注射重组质粒pcDNA3.1-amastin和空质粒pcDNA3.1(+)(50μg/只),2周后同法加强免疫1次。加强免疫后第7、14和21天每组各取小鼠3只,内眦采血,分离血清,间接ELISA法测定血清中抗原特异性抗体水平。随后脱颈处死小鼠,无菌取脾,分离脾细胞,用刀豆球蛋白A刺激培养,3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法检测脾淋巴细胞增殖活性和细胞毒性T淋巴细胞(CTL)杀伤活性。双抗体夹心ELISA法检测脾淋巴细胞培养上清中γ干扰素(IFN-γ)、白细胞介素-2(IL-2)和IL-4的水平。结果加强免疫后第7、14和21天,实验组均检测到特异性IgG抗体,效价在1∶640以上,而对照组未检测到IgG抗体(P<0.01);实验组脾淋巴细胞增殖活性刺激指数分别为4.28±0.51、5.01±0.60和4.39±0.50,均高于对照组(P<0.01);实验组脾淋巴细胞培养上清中IFN-γ含量分别为(42.06±4.26)、(66.02±6.02)和(58.29±3.75)pg/ml,IL-2含量分别为(38.21±5.11)、(64.79±8.67)和(52.69±7.15)pg/ml,均高于对照组(P<0.01),两组均未检测到IL-4;实验组脾淋巴细胞CTL杀伤活性分别为(42.20±5.96)%、(63.66±5.44)%和(52.24±4.56)%,均高于对照组(P<0.01)。结论杜氏利什曼原虫无鞭毛体蛋白基因重组质粒pcDNA3.1-amastin免疫小鼠后可诱导其产生特异的体液免疫应答和Th1型细胞免疫应答。 Objective To investigate the immunogenicity of recombinant plasmid pcDNA3.1-amastin with Leishmania donovani amastin gene.Methods Eighteen female BALB/c mice were randomly divided into experimental group and control group.Mice in experimental group and control group were intramuscularly injected with 50 μg recombinant plasmid pcDNA3.1-amastin and blank plasmid vector pcDNA3.1(+),respectively,and then received equivalent dose of plamid after 2 weeks.On days 7,14,and 21 after the second immunization,serum samples were collected from 3 mice each group.The mice were then sacrificed,spleens were removed and splenocytes were collected.Serum antibody level was determined by indirect ELISA.Splenocyte proliferation responses and cytotoxicity of spleen-derived lymphocytes were analyzed by MTT colorimetry after stimulation with ConA.Level of IFN-γ,IL-2 and IL-4 in the splenocyte culture supernatants was determined by double antibody sandwich ELISA.Results On days 7,14,and 21 after the second immunization,specific IgG antibody(more than 1 ∶ 640) was found in experimental group,but not in the control(P0.01);stimulation index(SI) of spleen cells in experimental group(4.28±0.51,5.01±0.60,and 4.39±0.50) was higher than that of control group(P0.01);the level of IFN-γ[(42.06±4.26),(66.02±6.02),and(58.29±3.75) pg/ml] and IL-2 [(38.21±5.11),(64.79±8.67),and(52.69±7.15) pg/ml] in splenocyte culture supernatants of experimental group was higher than that of control group(P0.01);IL-4 was not found in the two groups;cytotoxicity of spleen-derived lymphocytes in experimental group [(42.20±5.96)%,(63.66±5.44)%,and(52.24±4.56)%]was stronger than that of control(P0.01).Conclusion The recombinant plasmid pcDNA3.1-amastin can induce specific humoral and Th1 type cellular immune responses in mice.
出处 《中国寄生虫学与寄生虫病杂志》 CAS CSCD 北大核心 2011年第2期122-125,共4页 Chinese Journal of Parasitology and Parasitic Diseases
基金 国家自然科学基金(No.30771883) 贵州省科学技术基金(黔科合J字[2008]2279号)~~
关键词 杜氏利什曼原虫 无鞭毛体蛋白 基因疫苗 免疫原性 Leishmania donovani Amastin DNA vaccine Immunogenicity
  • 相关文献

参考文献7

  • 1Boelaert M. Criel B. Leeuwenburg J, et al. Visceral teishmaniasis control: a public health perspective [J]. Trans R Soc Trop Med Hyg 2000. 94(5): 465-471.
  • 2Rochette A, McNicoll F, Girard J, et al. Characterization and developmental gene regulation of a large gene family encoding amastin surface proteins in Leishmania spp.[J]. Mol Biochem Parasitol, 2005, 140(2): 205-220.
  • 3Salotra P, Duncan RC, Singh R, et al. Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis[J] . Microbes Infect, 2006, 8(3) : 637-644.
  • 4Stober CB, Lange UG, Roberts MT, et al. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against routine Leishnumia major infection[J]. Vaccine, 2006, 24 (14): 2602-2616.
  • 5李金福,陈建平,田玉,杨志伟,马莹,胡孝素.杜氏利什曼原虫四川分离株无鞭毛体蛋白基因的克隆及真核表达[J].中国寄生虫学与寄生虫病杂志,2007,25(2):124-128. 被引量:2
  • 6Fragaki K. Suffia I, Ferrua B. et al. Immunization with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters[J]. Vaccine, 2001, 19(13-14): 1701-1709.
  • 7Bindu S, Poonam T, Shailendra S, et al. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani[ J ]. Vaccine, 2003, 21(11-12) : 1292-1299.

二级参考文献6

  • 1Teixeira SM,Russell DG,Kirchhoff CY,et al.Differentially expressed gene family encoding "amastin",a surface protein of Trypanosoma cruzi amastigotes[J].J Biol Chem,1994,269:20509-20516.
  • 2Smyth AJ,Ghosh A,Hassan MQ,et al.Rapid and sensitive detection of leishmania kinetoplast DNA from spleen and blood samples of kala-azar patients[J].Parasitology,1992,105:183-192.
  • 3Wu Y,El Fakhry Y,Sereno D,et al.A new developmentally regulated gene family in Leishmania amastigotes encoding a homolog of amastin surface proteins[J].Mol Biochem Parasitol,2000,110:345-357.
  • 4Salotra P,Duncan RC,Singh R,et al.Upregulation of surface proteins in Leishmania donovani isolated from patients of post kalaazar dermal leishmaniasis[J].Microbes Infect,006,8:637-644.
  • 5Stober CB,Lange UG,Roberts MT,et al.From genome to vaccines for leishmaniasis:screening 100 novel vaccine candidates against murine Leishmania major infection[J].Vaccine,2006,24:2602-2616.
  • 6成军,钟彦伟,刘妍,董菁,杨继珍,陈菊梅.利什曼原虫无鞭毛体蛋白的基因克隆化与序列分析[J].中华传染病杂志,2001,19(1):27-31. 被引量:28

共引文献1

同被引文献27

  • 1Julia V, Rassoulzadegan M, Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen [ J ]. Science, 1996, 274(5286) : 421-423.
  • 2Paraguai de Souza E, Bemardo RR, Palatnik M, et al. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani [J]. Vaccine, 2001, 19(23/24): 3104-3115.
  • 3Borja-Cabrera GP, Correia Pontes NN, da Silva VO, et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Gon c alo do Amarante, RN) [J]. Vaccine, 2002, 20(27/28): 3277-3284.
  • 4Agallou M, Margaroni M, Karagouni E. Cellular vaccination with bone marrow-derived dendritic ceils pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis [ J ]. Vaccine, 2011, 29(31 ): 5053-5064.
  • 5Whitaker SM, Colmenares M, Pestana KG, et al. Leishmania pifanoi proteoglycolipid complex 178 induces macrophage cytokine production through Toll-like receptor 4 [ J ]. Infect Immun, 2008, 76(5) : 2149-2156.
  • 6Lemesre JL, Holzmuller P, Goncalves RB, et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp- MDP vaccine in endemic areas of France : double-blind randomised efficacy field trial [J]. Vaccine, 2007, 25(21 ) : 4223-4234.
  • 7Goto Y, Bhatia A, Raman VS, et al. Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross- protection against L. major infection [ J ]. Vaccine, 2009, 27(21 ) : 2884-2890.
  • 8Goto Y, Bhatia A, Raman VS, et al. KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis [ J ]. Clin Vaccine Immunol, 2011, 18(7) : 1118-1124.
  • 9Duthie MS, Raman VS, Piazza FM, et al. The development and clinical evaluation of second-generation leishmaniasis vaccines [J]. Vaccine, 2012, 30(2) : 134-141.
  • 10Sakai S, Takashima Y, Matsumoto Y, et al. Intranasal immunization with Leish-111 f induces IFN-gamma production and protects mice from Leishmania major infection [ J ]. Vaccine, 2010, 28(10): 2207-2213.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部